Amicus Therapeutics Inc. | Mutual Funds
Mutual Funds that own Amicus Therapeutics Inc.
Fidelity Magellan Fund
5,211,934
2.76%
0
0.38%
07/31/2018
Vanguard Small Cap Index Fund
4,742,706
2.5%
62,420
0.07%
07/31/2018
Vanguard Total Stock Market Index Fund
4,698,604
2.48%
5,382
0.01%
07/31/2018
SPDR S&P Biotech ETF
4,629,714
2.45%
11,910
1.07%
09/06/2018
iShares Russell 2000 ETF
3,971,348
2.1%
-2,121
0.11%
09/06/2018
Fidelity Select Biotechnology Portfolio
3,953,862
2.09%
0
0.57%
07/31/2018
Prudential Jennison Health Sciences Fund
3,136,734
1.66%
0
1.66%
07/31/2018
Janus Triton Fund
2,964,489
1.57%
0
0.34%
06/30/2018
Prudential Jennison Small Company Fund, Inc.
2,771,938
1.47%
-48,342
0.99%
07/31/2018
Vanguard Small Cap Growth Index Fund
2,709,305
1.43%
41,391
0.14%
07/31/2018
| Address |
1 Cedar Brook Drive
Cranbury New Jersey 08512
United States
|
|
Employees
|
- |
| Website |
http://www.amicusrx.com |
| Updated |
07/08/2019 |
| Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |
